



JUN 2 - 2005

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Sterdent Corporation  
C/O Mr. Thomas L. Creel  
Kenyon & Kenyon, Reilly, Carr, & Chapin  
59 Maiden Lane  
New York, New York 10038

Re: K770667

Trade/Device Name: Chromascan™  
Regulation Number: 21 CFR 872.3661  
Regulation Name: Optical Impression Systems for CAD/CAM  
Regulatory Class: II  
Product Code: KZN  
Dated: April 05, 1977  
Received: April 08, 1977

Dear Mr. Creel:

This letter corrects our substantially equivalent letter of April 18, 1977, regarding the classification of your device which was not identified.

We have reviewed your Section 510(k) notification of intent to market the device referenced above and have determined the device is substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Pre-market Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, FDA will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, the Food and Drug Administration (FDA) may publish further announcements concerning your device in the Federal Register.

Page 2 – Mr. Thomas L. Creel

Please note: this response to your premarket notification submission does not affect any obligation you might have under sections **531** through **542** of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your **510(k)** premarket notification. An FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market, but it does not mean that FDA **approves** your device. Therefore, you may not promote or in any way represent your device or its labeling as being **approved** by FDA.

If you desire specific advice for your device on our labeling regulation (21 CFR Part **801** and additionally **809.10** for in vitro diagnostic devices), please contact the Office of Compliance at **(240) 276-0115**. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at **(301) 594-4639**. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number **(800) 638-2041** or at **(301) 443-6597**.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Chiu S. Lin', with a stylized flourish at the end.

Chiu S. Lin, PhD

Director

Division of Anesthesiology, General Hospital,

Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and

Radiological Health